RAF1 promotes lymphatic metastasis of hypopharyngeal carcinoma via regulating LAGE1: an experimental research

Abstract

Background Lymphatic metastasis was an independent prognostic risk factor for hypopharyngeal carcinoma and was the main cause of treatment failure. The purpose of this study was to screen the differential genes and investigate the mechanism of lymphatic metastasis in hypopharyngeal carcinoma. Methods Transcriptome sequencing was performed on primary tumors of patients, and differential genes were screened by bioinformatics analysis. The expression of differential genes was verified by qRT-PCR, western-blotting and immunohistochemical, and prognostic value was analyzed by Kaplan–Meier and log-rank test and Cox’s test. Next, FADU and SCC15 cell lines were used to demonstrate the function of differential genes both in vitro by EdU, Flow cytometry, Wound Healing and Transwell assays and in vivo by a foot-pad xenograft mice model. Proteomic sequencing was performed to screen relevant targets. In addition, in vitro and in vivo experiments were conducted to verify the mechanism of lymphatic metastasis. Results Results of transcriptome sequencing showed that RAF1 was a significantly differential gene in lymphatic metastasis and was an independent prognostic risk factor. In vitro experiments suggested that decreased expression of RAF1 could inhibit proliferation, migration and invasion of tumor cells and promote apoptosis. In vivo experiments indicated that RAF1 could promote tumor growth and lymphatic metastasis. Proteomic sequencing and subsequent experiments suggested that LAGE1 could promote development of tumor and lymphatic metastasis, and was regulated by RAF1. Conclusions It suggests that RAF1 can promote lymphatic metastasis of hypopharyngeal carcinoma by regulating LAGE1, and provide a basis for the exploring of novel therapeutic target and ultimately provide new guidance for the establishment of intelligent diagnosis and precise treatment of hypopharyngeal carcinoma.

FSCN1/METTL3/TLN1 axis promotes the malignant progression in bladder carcinoma

“…In this study, we found that FSCN1 promotes the invasion and metastasis of BLCA cells by directly binding to and inhibiting the TLN1, RAF1, CDC42, VAV2 and GRB2 mRNAs. RAF1 regulates the progression of endometrial cancer and hypopharyngeal cancer [27,28], CDC42 promotes metastasis in hepatocellular carcinoma [29], and TLN1 has a pro-metastatic function in prostate cancer [30]. Therefore, we hypothesize that FSCN1 forms an RBP regulatory network with multiple mRNAs, which is the molecular basis of the metastasis in various tumors.…”

Identification of a new anoikis-related gene signature for prognostic significance in head and neck squamous carcinomas

“…The American Cancer Society placed HNSCC as the sixth most prevalent cancer, which constituted 5.3% to 7.1% of all systemic malignancies. [29] In the case of HNSCC, metastasis is the leading contributor to treatment failure. [30] As a result, it is crucial to come up with a prognostic model to promote the development of treatment methods for HNSCC.…”

Genetic causes of lymphatic disorders: recent updates on the clinical and molecular aspects of lymphatic disease

“…Several new presentation patterns and genetic causes of lymphatic disorders have been identified (Table 2) [11,13,14–16,19–23,35 ▪ ,50–57]. The Eph-ephrin signalling cascade is implicated in many developmental processes, including the regulation of vascular endothelial growth factor through ephrinB 2 [28].…”